Praxis Precision Medicines to Present at Citi’s 16th Annual BioPharma Virtual Conference
September 01, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
August 16, 2021 07:55 ET
|
Praxis Precision Medicines, Inc.
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile ...
Praxis Precision Medicines to Present at 2021 Wedbush PacGrow Healthcare Conference
August 02, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
July 06, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
May 25, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
May 14, 2021 09:00 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Prices Public Offering of Common Stock
May 13, 2021 22:39 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
May 11, 2021 16:22 ET
|
Praxis Precision Medicines, Inc.
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 11, 2021 08:00 ET
|
Praxis Precision Medicines, Inc.
Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for...